Company news
Syntara Limited (ASX:SNT) news
Syntara Limited news releases on 6ix. Latest, Oct 6, 2026: Further significant results from SNT-4728 iRBD Phase 2 trial
Press releases & updates
Further significant results from SNT-4728 iRBD Phase 2 trial
October 6, 2026
Syntara expands SNT-9465 skin scarring study
September 30, 2026
Appendix 4E and Annual Report
August 27, 2026
Encouraging SNT-4728 Phase 2 iRBD results
July 5, 2026
Results of Share Purchase Plan
June 10, 2026
Share Purchase Plan Offer Booklet
May 13, 2026
$8m placement and share purchase plan
April 29, 2026
Continuation of trading halt
April 28, 2026
Positive FDA feedback for Amsulostat P2b trial
April 27, 2026
Half Year Report and Appendix 4D
February 25, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 28, 2026
Amsulostat and Garvan in MRFF funded pancreatic trial
January 20, 2026
SNT-4728 Phase 2 iRBD Parkinsons UK Trial fully recruited
January 7, 2026
Skin scarring program to progress on positive Phase1a result
November 25, 2025
Quarterly Shareholder Report and Appendix 4C
October 27, 2025
Positive top-line Phase 2a data confirms competitive profile
September 29, 2025
Preliminary Final Report
August 28, 2025
Guidance from FDA on amsulostat clinical progression
August 11, 2025
Reinstatement to Quotation
August 4, 2025
Suspension from Quotation
July 31, 2025
Quarterly Appendix 4C Cash Flow Report
July 31, 2025
Quarterly Shareholder Report
July 30, 2025
New positive interim data in Phase 2 study of SNT-5505
June 12, 2025
SNT-5505 awarded US FDA Fast Track designation
June 9, 2025
Quarterly Activities Report
April 29, 2025
Acceleration of skin scarring program
March 17, 2025
Placement
December 11, 2024
Equity Raising Presentation
December 11, 2024
Interim data in Phase 2 study of SNT-5505 in myelofibrosis
December 10, 2024
Presentation: Phase 2 study of SNT-5505 in myelofibrosis
December 10, 2024
Trading Halt
December 9, 2024
Response to ASX Price Query
December 4, 2024
Pause in Trading
December 3, 2024
Appendix 4E and Annual Report to shareholders
August 30, 2024
Half Yearly Report and Accounts
February 29, 2024
PXS Company Restructure Sale of Mannitol Business
October 2, 2023
PXS to Receive Prepayment of 2023 Research Tax Incentive
August 7, 2023
Final Set of Interim Data from PXS-5505 in Myelofibrosis
July 12, 2023
PXS Announces Encouraging Results from Phase 1c Scar Study
May 23, 2023
After FDA Review PXS Accelerates Plans for Combination Study
April 11, 2023
PXS announces positive interim data from myelofibrosis trial
October 18, 2022
Investor Presentation
October 18, 2022
PXS Releases Promising Interim Data from Skin Scarring Study
September 25, 2022
PXS to Receive Stg2.9m from Parkinsons UK for New Trial
August 31, 2022
Aptar Pharma Pays PXS Us$5m to Acquire Orbital Technology
August 4, 2022
Clarification Announcement
May 13, 2022
Appendix 4C Quarterly Cash Flow Report
April 28, 2022
Response to ASX Aware Query
January 10, 2022
PXS Collaborators Receive Government Grants of $1.4m
January 5, 2022
Share Purchase Plan
December 20, 2021